Biocon’s arm receives Rs 1,125 crore capital injection from Goldman Sachs

09 Nov 2020 Evaluate

Biocon’s subsidiary company -- Biocon Biologics’ board has approved a Rs 1,125 crore ($150 million) capital injection from Goldman Sachs. As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions. This capital injection by Goldman Sachs will enable Biocon Biologics to make prudent investments in R&D, high-quality manufacturing, as well as, establish a global commercial footprint.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

360.85 -9.25 (-2.50%)
30-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1757.35
Dr. Reddys Lab 1254.65
Cipla 1223.05
Zydus Lifesciences 871.20
Lupin 2312.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×